These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1775 related items for PubMed ID: 15748904

  • 21. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 24. Development of Herceptin resistance in breast cancer cells.
    Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP.
    Cytometry A; 2004 Feb; 57(2):86-93. PubMed ID: 14750129
    [Abstract] [Full Text] [Related]

  • 25. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D, Panosa C, Menendez JA, Puig T, Oliveras G, Pandiella A, De Llorens R, Massaguer A.
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [Abstract] [Full Text] [Related]

  • 26. Antihuman epidermal growth factor receptor 2 antibody herceptin inhibits autocrine motility factor (AMF) expression and potentiates antitumor effects of AMF inhibitors.
    Talukder AH, Bagheri-Yarmand R, Williams RR, Ragoussis J, Kumar R, Raz A.
    Clin Cancer Res; 2002 Oct; 8(10):3285-9. PubMed ID: 12374700
    [Abstract] [Full Text] [Related]

  • 27. Stroma cells: a novel target of herceptin activity.
    Corsini C, Mancuso P, Paul S, Burlini A, Martinelli G, Pruneri G, Bertolini F.
    Clin Cancer Res; 2003 May; 9(5):1820-5. PubMed ID: 12738740
    [Abstract] [Full Text] [Related]

  • 28. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X.
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [Abstract] [Full Text] [Related]

  • 29. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 30. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X, Xu L, Yu J, Fang X.
    Exp Cell Res; 2009 Oct 01; 315(16):2847-55. PubMed ID: 19497323
    [Abstract] [Full Text] [Related]

  • 31. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells.
    Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE.
    Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791
    [Abstract] [Full Text] [Related]

  • 32. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.
    Oncogene; 2007 Nov 01; 26(50):7163-9. PubMed ID: 17525746
    [Abstract] [Full Text] [Related]

  • 33. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT, Metz MZ, Kane SE.
    Breast Cancer Res Treat; 2005 May 01; 91(2):187-201. PubMed ID: 15868447
    [Abstract] [Full Text] [Related]

  • 34. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 01; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 35. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.
    Breast Cancer Res Treat; 2008 Nov 01; 112(1):25-33. PubMed ID: 18060492
    [Abstract] [Full Text] [Related]

  • 36. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
    Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, Fong WF.
    Cancer Chemother Pharmacol; 2011 Nov 01; 68(5):1315-23. PubMed ID: 21461888
    [Abstract] [Full Text] [Related]

  • 37. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE, Serrero G.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [Abstract] [Full Text] [Related]

  • 38. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z, Barnes CJ, Kumar R.
    Clin Cancer Res; 2004 Jun 01; 10(11):3621-8. PubMed ID: 15173068
    [Abstract] [Full Text] [Related]

  • 39. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, Ethier SP.
    Mol Carcinog; 1996 Mar 01; 15(3):227-38. PubMed ID: 8597535
    [Abstract] [Full Text] [Related]

  • 40. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 01; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 89.